TRi-1

TRi-1 is a novel small molecule inhibitor specifically targeting thioredoxin reductase 1 (TXNRD1), a selenoprotein essential for cellular antioxidant defense. Developed as a more specific alternative to auranofin, TRi-1 aims to achieve potent anticancer efficacy while minimizing off-target mitochondrial toxicity. By inhibiting TXNRD1, the drug disrupts the redox balance in cancer cells, which often exhibit high levels of reactive oxygen species (ROS) and a heightened dependency on antioxidant systems for survival. Preclinical studies in melanoma and lung adenocarcinoma models have demonstrated its potential as a targeted anticancer agent with superior specificity compared to other thioredoxin reductase inhibitors like TRi-2 and auranofin.